The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1

Romina M. Wiedmann, Karin Von Schwarzenberg, Andrea Palamidessi, Laura Schreiner, Rebekka Kubisch, Johanna Liebl, Christina Schempp, Dirk Trauner, Gyorgy Vereb, Stefan Zahler, Ernst Wagner, Rolf Müller, Giorgio Scita, Angelika M. Vollmar

Research output: Contribution to journalArticle

Abstract

The abundance of the multimeric vacuolar ATP-dependent proton pump, V-ATPase, on the plasma membrane of tumor cells correlates with the invasiveness of the tumor cell, suggesting the involvement of V-ATPase in tumor metastasis. V-ATPase is hypothesized to create a proton efflux leading to an acidic pericellular microenvironment that promotes the activity of proinvasive proteases. An alternative, not yet explored possibility is that V-ATPase regulates the signaling machinery responsible for tumor cell migration. Here, we show that pharmacologic or genetic reduction of V-ATPase activity significantly reduces migration of invasive tumor cells in vitro. Importantly, the V-ATPase inhibitor archazolid abrogates tumor dissemination in a syngeneic mouse 4T1 breast tumor metastasis model. Pretreatment of cancer cells with archazolid impairs directional motility by preventing spatially restricted, leading edge localization of epidermal growth factor receptor (EGFR) as well as of phosphorylated Akt. Archazolid treatment or silencing of V-ATPase inhibited Rac1 activation, as well as Rac1-dependent dorsal and peripheral ruffles by inhibiting Rab5-mediated endocytotic/exocytotic trafficking of Rac1. The results indicate that archazolid effectively decreases metastatic dissemination of breast tumors by impairing the trafficking and spatially restricted activation of EGFR and Rho-GTPase Rac1, which are pivotal for directed movement of cells. Thus, our data reveals a novel mechanism underlying the role of V-ATPase in tumor dissemination.

Original languageEnglish (US)
Pages (from-to)5976-5987
Number of pages12
JournalCancer Research
Volume72
Issue number22
DOIs
StatePublished - Nov 15 2012

Fingerprint

rho GTP-Binding Proteins
Adenosine Triphosphatases
Neoplasm Metastasis
Neoplasms
Epidermal Growth Factor Receptor
Cell Movement
Breast Neoplasms
Proton Pumps
Protons
Peptide Hydrolases
Adenosine Triphosphate
Cell Membrane

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wiedmann, R. M., Von Schwarzenberg, K., Palamidessi, A., Schreiner, L., Kubisch, R., Liebl, J., ... Vollmar, A. M. (2012). The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Research, 72(22), 5976-5987. https://doi.org/10.1158/0008-5472.CAN-12-1772

The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. / Wiedmann, Romina M.; Von Schwarzenberg, Karin; Palamidessi, Andrea; Schreiner, Laura; Kubisch, Rebekka; Liebl, Johanna; Schempp, Christina; Trauner, Dirk; Vereb, Gyorgy; Zahler, Stefan; Wagner, Ernst; Müller, Rolf; Scita, Giorgio; Vollmar, Angelika M.

In: Cancer Research, Vol. 72, No. 22, 15.11.2012, p. 5976-5987.

Research output: Contribution to journalArticle

Wiedmann, RM, Von Schwarzenberg, K, Palamidessi, A, Schreiner, L, Kubisch, R, Liebl, J, Schempp, C, Trauner, D, Vereb, G, Zahler, S, Wagner, E, Müller, R, Scita, G & Vollmar, AM 2012, 'The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1', Cancer Research, vol. 72, no. 22, pp. 5976-5987. https://doi.org/10.1158/0008-5472.CAN-12-1772
Wiedmann RM, Von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J et al. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Research. 2012 Nov 15;72(22):5976-5987. https://doi.org/10.1158/0008-5472.CAN-12-1772
Wiedmann, Romina M. ; Von Schwarzenberg, Karin ; Palamidessi, Andrea ; Schreiner, Laura ; Kubisch, Rebekka ; Liebl, Johanna ; Schempp, Christina ; Trauner, Dirk ; Vereb, Gyorgy ; Zahler, Stefan ; Wagner, Ernst ; Müller, Rolf ; Scita, Giorgio ; Vollmar, Angelika M. / The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. In: Cancer Research. 2012 ; Vol. 72, No. 22. pp. 5976-5987.
@article{bc9e8c7118154f6ab12b26542c97b2cd,
title = "The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1",
abstract = "The abundance of the multimeric vacuolar ATP-dependent proton pump, V-ATPase, on the plasma membrane of tumor cells correlates with the invasiveness of the tumor cell, suggesting the involvement of V-ATPase in tumor metastasis. V-ATPase is hypothesized to create a proton efflux leading to an acidic pericellular microenvironment that promotes the activity of proinvasive proteases. An alternative, not yet explored possibility is that V-ATPase regulates the signaling machinery responsible for tumor cell migration. Here, we show that pharmacologic or genetic reduction of V-ATPase activity significantly reduces migration of invasive tumor cells in vitro. Importantly, the V-ATPase inhibitor archazolid abrogates tumor dissemination in a syngeneic mouse 4T1 breast tumor metastasis model. Pretreatment of cancer cells with archazolid impairs directional motility by preventing spatially restricted, leading edge localization of epidermal growth factor receptor (EGFR) as well as of phosphorylated Akt. Archazolid treatment or silencing of V-ATPase inhibited Rac1 activation, as well as Rac1-dependent dorsal and peripheral ruffles by inhibiting Rab5-mediated endocytotic/exocytotic trafficking of Rac1. The results indicate that archazolid effectively decreases metastatic dissemination of breast tumors by impairing the trafficking and spatially restricted activation of EGFR and Rho-GTPase Rac1, which are pivotal for directed movement of cells. Thus, our data reveals a novel mechanism underlying the role of V-ATPase in tumor dissemination.",
author = "Wiedmann, {Romina M.} and {Von Schwarzenberg}, Karin and Andrea Palamidessi and Laura Schreiner and Rebekka Kubisch and Johanna Liebl and Christina Schempp and Dirk Trauner and Gyorgy Vereb and Stefan Zahler and Ernst Wagner and Rolf M{\"u}ller and Giorgio Scita and Vollmar, {Angelika M.}",
year = "2012",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-12-1772",
language = "English (US)",
volume = "72",
pages = "5976--5987",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1

AU - Wiedmann, Romina M.

AU - Von Schwarzenberg, Karin

AU - Palamidessi, Andrea

AU - Schreiner, Laura

AU - Kubisch, Rebekka

AU - Liebl, Johanna

AU - Schempp, Christina

AU - Trauner, Dirk

AU - Vereb, Gyorgy

AU - Zahler, Stefan

AU - Wagner, Ernst

AU - Müller, Rolf

AU - Scita, Giorgio

AU - Vollmar, Angelika M.

PY - 2012/11/15

Y1 - 2012/11/15

N2 - The abundance of the multimeric vacuolar ATP-dependent proton pump, V-ATPase, on the plasma membrane of tumor cells correlates with the invasiveness of the tumor cell, suggesting the involvement of V-ATPase in tumor metastasis. V-ATPase is hypothesized to create a proton efflux leading to an acidic pericellular microenvironment that promotes the activity of proinvasive proteases. An alternative, not yet explored possibility is that V-ATPase regulates the signaling machinery responsible for tumor cell migration. Here, we show that pharmacologic or genetic reduction of V-ATPase activity significantly reduces migration of invasive tumor cells in vitro. Importantly, the V-ATPase inhibitor archazolid abrogates tumor dissemination in a syngeneic mouse 4T1 breast tumor metastasis model. Pretreatment of cancer cells with archazolid impairs directional motility by preventing spatially restricted, leading edge localization of epidermal growth factor receptor (EGFR) as well as of phosphorylated Akt. Archazolid treatment or silencing of V-ATPase inhibited Rac1 activation, as well as Rac1-dependent dorsal and peripheral ruffles by inhibiting Rab5-mediated endocytotic/exocytotic trafficking of Rac1. The results indicate that archazolid effectively decreases metastatic dissemination of breast tumors by impairing the trafficking and spatially restricted activation of EGFR and Rho-GTPase Rac1, which are pivotal for directed movement of cells. Thus, our data reveals a novel mechanism underlying the role of V-ATPase in tumor dissemination.

AB - The abundance of the multimeric vacuolar ATP-dependent proton pump, V-ATPase, on the plasma membrane of tumor cells correlates with the invasiveness of the tumor cell, suggesting the involvement of V-ATPase in tumor metastasis. V-ATPase is hypothesized to create a proton efflux leading to an acidic pericellular microenvironment that promotes the activity of proinvasive proteases. An alternative, not yet explored possibility is that V-ATPase regulates the signaling machinery responsible for tumor cell migration. Here, we show that pharmacologic or genetic reduction of V-ATPase activity significantly reduces migration of invasive tumor cells in vitro. Importantly, the V-ATPase inhibitor archazolid abrogates tumor dissemination in a syngeneic mouse 4T1 breast tumor metastasis model. Pretreatment of cancer cells with archazolid impairs directional motility by preventing spatially restricted, leading edge localization of epidermal growth factor receptor (EGFR) as well as of phosphorylated Akt. Archazolid treatment or silencing of V-ATPase inhibited Rac1 activation, as well as Rac1-dependent dorsal and peripheral ruffles by inhibiting Rab5-mediated endocytotic/exocytotic trafficking of Rac1. The results indicate that archazolid effectively decreases metastatic dissemination of breast tumors by impairing the trafficking and spatially restricted activation of EGFR and Rho-GTPase Rac1, which are pivotal for directed movement of cells. Thus, our data reveals a novel mechanism underlying the role of V-ATPase in tumor dissemination.

UR - http://www.scopus.com/inward/record.url?scp=84869233061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869233061&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-1772

DO - 10.1158/0008-5472.CAN-12-1772

M3 - Article

VL - 72

SP - 5976

EP - 5987

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -